ReviewJournal of neurogastroenterology and motility2022
Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider.
Review in Journal of neurogastroenterology and motility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Initiating multi-strain probiotics is associated with clinically meaningful symptom relief, better quality of life, and fewer treatment escalations in IBS-D/IBS-M: a Chinese real-world propensity-matched cohort study.Frontiers in medicine · 2026Article
- Probiotic Development Strategy Centered on Stability and Regulatory Considerations.Comprehensive reviews in food science and food safety · 2026Review
- Alteration in gut microbiota after colonoscopy: proposed mechanisms and the role of probiotic interventions.Clinical endoscopy · 2025Review
- The Effects of Fermented Rice Drink WithJournal of neurogastroenterology and motility · 2024Article
- Review
- The Long and Winding Road to the Best Clinical Research and Personalized Therapy With Probiotics: Do Not Forget Host Physiology.Journal of neurogastroenterology and motility · 2023Article
- [Brain-Gut-Microbiota Axis].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics.Frontiers in microbiology · 2023Review
- Clinical research with probiotics as an indicator of global valorization since the year 2000.Frontiers in microbiology · 2023Article
- Isolation and characterization of lactic acid bacteria with potential probiotic activity and further investigation of their activity by α-amylase and α-glucosidase inhibitions of fermented batters.Frontiers in microbiology · 2022Article
- Editorial: Neuroendocrine signalling pathways along the microbiota-gut-brain axis in functional gut disorders.Frontiers in endocrinology · 2022Article
- Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producingGut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotic products in various formulations are widely used world-wide for a seemingly limitless range of indications--from health maintenance to the alleviation of common intestinal ailments and on to the prevention and treatment of a variety of gastrointestinal diseases and disorders. The profusion of probiotic preparations, together with a very different regulatory climate compared to that which surrounds drugs and devices, leaves the consumer and the health care professional alike bewildered. How can they tell which products truly are what they claim to be? Which probiotics should be chosen for a particular clinical situation? These questions are thrown into stark relief when one evaluates the literature on probiotics in irritable bowel syndrome. To provide some guidance the current probiotic landscape is reviewed and some achievable steps to help bring light to a murky environment are proposed. The goal is to promote verifiable quality control and generate actionable evidence from well-conducted clinical trials of probiotic products in irritable bowel syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.